Solvonis Therapeutics PLC (LSE:SVNS) Anthony Tennyson talked with Proactive about the company’s progress following its acquisition of Awakn Life Sciences and the advancement of its lead programs targeting central nervous system (CNS) disorders.
Tennyson outlined how the acquisition strengthens Solvonis’s pipeline, bringing late clinical-stage assets in AUD and psychiatry, specifically a joint venture for post-traumatic stress disorder. “With the acquisition of Awakn we're able to acquire linked clinical stage programs within addiction for alcohol use disorder and then acquire the full joint venture program... in Psychiatry for post-traumatic stress disorder,” he said.
The company’s lead program, SVN-001, is currently in a Phase 3 trial in partnership with the University of Exeter and the UK Department of Health. Recruitment began in July 2024, with results expected in late 2027 or early 2028. Solvonis is in licensing discussions with several pharmaceutical firms for this asset.
Tennyson also provided an update on SVN-002, which targets the US market. The FDA has agreed to a regulatory path that could bypass early-stage trials, significantly reducing costs.
Key 2025 milestones include: progressing licensing for SVN-001, establishing a scientific bridge for SVN-002, and declaring a lead candidate for SVN-SDN14.
For more videos like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and hit the notification bell to stay updated.
#Solvonis #AnthonyTennyson #AlcoholUseDisorder #SVN001 #SVN002 #CentralNervousSystem #BiotechNews #CNSDisorders #DrugDevelopment #PTSDTreatment #PharmaLicensing #SPRAVATO #AwaknLifeSciences #proactiveinvestors